Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | RHEB | Q15382 | 2/20 | 0.34 |
| ▸ | BRS3 | P32247 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.32 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
| ▸ | SYK | P43405 | 2/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7873651 | 0.89 | RHEB (0.34) | RHEBMAPK8MAPK10AR | |
| SCHEMBL7881897 | 0.87 | RHEB (0.40) | RHEB | |
| SCHEMBL7884557 | 0.86 | LOXL2 (0.40) | — | |
| SCHEMBL7877762 | 0.86 | DHODH (0.36) | BTKRHEBDHODHKDM4EPTGS2 | |
| SCHEMBL7881230 | 0.85 | RHEB (0.32) | RHEBMAPK8 | |
| SCHEMBL7873735 | 0.85 | RHEB (0.36) | RHEBAR | |
| SCHEMBL7879746 | 0.85 | RHEB (0.32) | RHEB | |
| SCHEMBL7881132 | 0.84 | RHEB (0.36) | RHEB | |
| SCHEMBL7880736 | 0.84 | SMN1; SMN2 (0.39) | BTKRHEBBRS3 | |
| SCHEMBL7878216 | 0.83 | RHEB (0.39) | RHEBAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |